Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

Amgen to push latecomer obesity drug into midstage testing

Sanofi, Amgen acknowledge Horizon interest as J&J steps back

Health Innovators – Monique Levy

Deep Dive: Digital Health 2022

ViiV Healthcare study reveals outdated perceptions of HIV

biological treatment

Celgene

Market Access/ News/ News

NICE recommends Celgene’s Ozanimod to treat ulcerative colitis

Nicole Raleigh biological treatment, Celgene, conventional therapy, drug approval, NICE, Ozanimod, ulcerative colitis, Zeposia 0 Comment

The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate

X

NICE recommends Celgene’s Ozanimod to treat ulcerative colitis

https://pharmaphorum.com/news/nice-recommends-celgenes-ozanimod-to-treat-ulcerative-colitis/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

Frontiers Health Steering Committee spotlight – Monique Levy

Frontiers Health Steering Committee spotlight – Monique Levy

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Most popular

Most Viewed

AstraZeneca, MSD raise prostate cancer awareness with 'Never Miss' campaign
Eisai's full lecanemab phase 3 trial results for Alzheimer's presented at CTAD
ViiV Healthcare study reveals outdated perceptions of HIV
Sanofi, Amgen acknowledge Horizon interest as J&J steps back
Expansion of CareQuest partnership with CIPCOH, funding '100 Million Mouths'

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com